News

Deal Announcements

Deciphera Pharma Adds To Series B

Wednesday, January 6, 2016 5:40:00 AM PDT | VentureDeal
   Waltham, Massachusetts  --  Deciphera Pharmaceuticals has raised $15 million in additional second round of venture capital investment, according to a company statement.

Deciphera is developing small molecule switch inhibitors of protein kinases for human clinical trials.

The company believes its kinase inhibitors address "multiple hallmarks of cancer."

SV Life Sciences made the $15 million add on to the company's Series B round, bringing the total for the round two $90 million.

The additional investment will be applied to the company's lead tumor targeting clinical programs.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1